No Closed Formularies In Medicaid Without Forgoing Rebates, CMS Tells Massachusetts
US agency decision is a relief to manufacturers worried that the Massachusetts plan would lead to reduced drug access and heavier rebate burdens.
You may also be interested in...
The innovator biopharma industry understandably concerned about a Trump Administration proposal to allow states to implement restrictive formularies while still collecting mandatory rebates. But the formulary protections in the Trump plan are an important message about the likely shape of any future changes to the US market.
Agency approves "first ever" supplemental rebate plan to enable value-based contracting a US state Medicaid program.